Our Technology

BIOMARK’S INTELLECTUAL PROPERTY
BIOMARK’S TECHNOLOGY PLATFORM
PUBLISHED SCIENTIFIC PAPERS AND PRINCIPALS
BIOMARK’S PIPELINE
CANCER TRENDS AND STATS IN THE USA
SCIENTIFIC ACHIEVEMENTS
STAGE OF DEVELOPMENT
PRODUCT ADVANTAGES
USA CANCER PREVENTION TOOLS

 

BIOMARK’S Intellectual Property

• Monoclonal and Polyclonal antibodies for Elisa kits and IVD point of care system

• New metabolome signature for cancer diagnosis

• Patent Applications Filed
– US Pat. 6811967
– mAB for Acetyl-amantadine
– New SSAT Substrates
– Analytical method for measuring SSAT activity
– Antibodies for anti-cancer therapeutic application
– Substrate detection using Raman IR
– Polyclonal antibody for IVD application

• Imaging applications using novel antibodies —under development

 

BioMark’s Technology Platform

1. SSAT (spermine/spermidine acetyltransferase) enzyme is up-regulated in tumour cells
2. Utilize SSAT1 activity as a biomarker for malignancy or in tumour tissue
3. Expand use of SSAT1 activity and SSAT 1 mRNA for potential new drug development / or other therapeutic applications

 

Published Scientific Papers and Principles

Amantadine is acetylated and excreted primarily in the urine. (Can J Physiol Pharmacol 1998;76:701)
The enzymes commonly known to acetylate drugs (NAT1 and NAT2) do not acetylate amantadine (Can J Physiol Pharmacol 1998;76:701)
Spermine/spermidine N1-acetyltransferase (SSAT) has been identified as the responsible enzyme for amantadine acetylation (Drug Metab Disposit 2001;29:676)
Spermine/spermidine acetyltransferase is up-regulated in tumor tissue (Biochem J 2003;376:1)
Amantadine can serve as a specific marker for spermine/spermidine acetyltransferase activity, and therefore also for the presence of cancer (Clin Pharmacol Ther 2006;79:PI-12)

 

BioMark’s Pipeline

 

 

 

 

 

 

 

 

 

 

 

 

 

Scientific Achievements

Animal model – transgenic mice
Cancer patient trial at Manitoba CancerCare
Metabolite quantification using LC MS
Control studies in Manitoba
ERB at University of Manitoba and CancerCare Manitoba
Urine stability studies – China and Canada
pK clinical trial in China – test and result
Lung cancer group test in China
Canadian healthy group result
Submission to Health Canada for CTA with new protocol – CTA Approved
PCR result, MTT assay result, preclinical trial result and implications
New anti tumour application and imaging – proof of concepts / principles – drug safety pre analysis
Raman AA/AM quantification at UVic
Increase specificity and sensitivity using  polyamine pathway – multi panel assay – under analysis
SSAT biology and pathway review and update

 

Stage of Development

Started phase III trial cancer diagnostics at Saint Boniface and a multi site study is underway to accelerate the completion of the trial in 2014. Appropriate healthy baseline studies will be conducted in each jurisdiction to comply with our Canadian trial
New Elisa kit prototypes have been completed and are being blind tested against LC MS standard
Generation of the monoclonal antibodies is expected to be completed by Qtr 1 2014 and IVD point of care device will be designed by Qtr 2 2014
Testing of Raman based technology will continue and results expected by Qtr 2 2014
Place diagnostic kits in markets following trials – in discussion with several potential customers
Commence response to treatment trial for lung cancer Qtr 2 2014
Commence in vivo studies on the antibody drug following successful cell line validation studies. Pending results in Qtr 2 , IND filing framework and resource requirements is underway.
Schedule meeting with Health Canada Qtr 2/3 2014

 

Product Advantages

ABA’s platform can allow for multiple early-stage tests; more than one type of cancer
Markers with better specificity and accuracy
Easy to use readers with easy to use screening application
Affordable
Consistent, reliable and reproducible results
Non-invasive – urine, saliva

 

USA Cancer Prevention Tools

Early screening and detection (mammograms, colon)
Early intervention
Lifestyle – diet, exercise and nutrition
Policy changes (smoke cessation)


Biomark’s products and technology are positioned to deliver effective solutions
to the emerging oncology market.

 

BioMark Technologies Summary

BioMark Summary (PDF)  [Right click to download]

Copyright 2014 by BioMark Tech. All Right Reserved.